Prehospital fibrinolytic therapy for ST-elevation acute myocardial infarction
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Despite advances in medications and interventional techniques, ST-segment elevation myocardial infarction (STEMI) remains a major cause of mortality in the United States. Reducing the time from the onset of symptoms to reperfusion (ischemic time) is the major determinant for mortality reduction. An ongoing controversy exists regarding whether there is more benefit of percutaneous coronary intervention (PCI) preceded by prehospital fibrinolytic treatment (facilitated PCI) compared with primary percutaneous coronary intervention (PPCI) in patients with STEMI. In different clinical trials, prehospital fibrinolysis markedly reduced the time from symptom onset to treatment, allowing earlier ST-segment elevation resolution and higher initial thrombolysis in myocardial infarction (TIMI) flow rates compared with PPCI. After prehospital fibrinolysis, patients who had subsequent PCI had lower in-hospital mortality rates and higher 1-year survival rates compared with those who underwent PPCI. In contrast, fulldose fibrinolytic agents without glycoprotein IIb/IIIa inhibitors immediately followed by PCI may increase major adverse events and should not be used.
- American Heart Association: Heart Disease and Stroke Statistics-2006 Update. Available at http://americanheart. org/statistics. Accessed June 2, 2009.
- Rathore SS, Cutis JP, Chen J, et al.: Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: a national cohort study. BMJ 2009, 339:b1807. CrossRef
- Nallamothu BK, Bates ER, Herrin J, et al.: Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005, 11:761–767. CrossRef
- Nallamothu BK, Bates ER: Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003, 92:824–826. CrossRef
- Brodie BR, Hansen C, Stuckey TD, et al.: Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 2006, 47:289–295. CrossRef
- De Luca G, Suryapranata H, Ottervanger JP, Antman EM: Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004, 109:1223–1225. CrossRef
- Weaver WD, Simes RJ, Betriu A, et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997, 278:2093–2098. CrossRef
- McNamara RL, Herrin J, Bradley EH, et al.: Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 2006, 47:45–51. CrossRef
- Gibson CM, Pride YB, Frederick PD: Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008, 156:1035–1044. CrossRef
- Boersma E, Maas AC, Deckers JW, et al.: Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996, 348:771–775. CrossRef
- Henry TD, Sharkey SW, Burke MN, et al.: A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 2007, 116:721–728. CrossRef
- Michel R, Derek Y, Richard D, et al.: A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008, 358:231–240. CrossRef
- Stone GW, Cox D, Garcia E, et al.: Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the Primary Angioplasty in Myocardial Infarction trials. Circulation 2001, 104:636–641. CrossRef
- Grines C, Patel A, Zijlstra F, et al.: Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003, 145:47–57. CrossRef
- Stringer KA: TIMI grade flow, mortality, and the GUSTO-III trial. Pharmacotherapy 1998, 18:699–705.
- Meijer A, Verheugt FW, Werter CJ, et al.: Aspirin versus coumadin in the prevention of re-occlusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993, 87:1524–1230.
- ADVANCE MI Investigators: Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005, 150:116–122. CrossRef
- Thiele H, Engelmann L, Elsner K, et al.: Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005, 26:1956–1963. CrossRef
- Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators: primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomized trial. Lancet 2006, 367:569–578.
- Keeley EC, Boura JA, Grines CL, et al.: Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomized trials. Lancet 2006, 367:579–588. CrossRef
- Maioli M, Bellandi F, Leoncini M, et al.: Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAX-AMI Trial). J Am Coll Cardiol 2007, 49:1517–1524. CrossRef
- Montalescot G, Borentain M, Payot L, et al.: Early versus late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004 292:362–366. CrossRef
- De Lemos JA, Antman EM, Gibson CM, et al.: Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation 2000, 101:239–243.
- Topol EJ, GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001, 357:1905–1914. CrossRef
- McKay RG, Dada MR, Jeffrey F, et al.: Comparison of outcomes and safety of “facilitated” versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2009, 103:316–321. CrossRef
- Schofield PM: Acute myocardial infarction: the case for pre-hospital thrombolysis with or without percutaneous coronary intervention. Heart 2005, 91(Suppl 3):iii7–iii11. CrossRef
- Morrow DA, Antman EM, Sayah A, Schuhwerk KC: Evaluation of the time saved by pre-hospital initiation of reteplase for ST-elevation myocardial infarction. J Am Coll Cardiol 2002, 40:71–77. CrossRef
- Roth A, Barbash GI, Hod H, et al.: Should thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study. J Am Coll Cardiol 1990, 15:932–936. CrossRef
- Weaver WD, Cerqueira M, Hallstrom AP, et al.: Pre-hospital-initiated vs. hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 1993, 270:1211–1216. CrossRef
- Morrison LJ, Verbeek PR, McDonald AC, et al.: Mortality and pre-hospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000, 283:2686–2692. CrossRef
- Denktas AE, Athar H, Henry TD, et al.: Reduced-dose fibrinolytic acceleration of ST-segment elevation myocardial infarction treatment coupled with urgent percutaneous coronary intervention compared to primary percutaneous coronary intervention alone. J Am Coll Cardiol Cardiovasc Interv 2008, 1:504–510.
- Danchin N, Blanchard D, Steg PG, et al.: Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004, 110:1909–1915. CrossRef
- Danchin N, Coste P, Ferrières J, et al.: Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Circulation 2008, 118:268–276. CrossRef
- Ellis SG, Tendera M, Belder MA, et al.: Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008, 358:2205–2217. CrossRef
- Stenestrand U, Lindbäck J, Wallentin L; RIKS-HIA Registry: Long-term outcome of primary percutaneous coronary intervention vs. pre-hospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006, 296:1749–1756. CrossRef
- Prehospital fibrinolytic therapy for ST-elevation acute myocardial infarction
Current Cardiovascular Risk Reports
Volume 3, Issue 5 , pp 339-344
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links